Testing the efficacy of a decision aid and planning tool for family building after cancer
- Institution
- Stanford University, CA
- Principal investigator
- Lidia Schapira
- Funding
- $593K
- Duration
- 2023–2028
Moonbase score
Still being scored
Abstract
Up to 93% of young adult female (YA-F) cancer survivors report fertility distress; 30-46% meet criteria for moderate-severe fertility-related trauma. Gonadotoxic cancer treatments can cause infertility, early menopause, or problems getting pregnant and carrying a pregnancy to term. Family building after cancer often requires in vitro fertilization, surrogacy, or adoption, which have medical/physical, psychosocial, financial, legal, and logistical barriers. Prior work shows that YA-Fs are unprepared for the challenges of family building after cancer, have unrealistic expectations (such as overestimating the likelihood of success), and risk missing their narrowed reproductive window and experiencing greater difficulty, distress, and higher costs than expected. The long-term goal of the proposed research is to improve oncofertility care in post-treatment survivorship. We propose to test the efficacy of the Roadmap to Parenthood software, an interactive web-based decision aid and planning tool for family building after cancer for YA-F survivors (18-45 years old) and explore its implementation potential. First, we will conduct a rigorous 12-month randomized controlled trial (Aim 1). YA-F cancer survivors (N=256) will be randomized into the (a) Roadmap intervention condition or (b) time and attention control condition that includes a web-based young adult cancer survivorship informational booklet. Surveys will be administered at baseline (pre-intervention) and 1-, 6-, and 12-month follow up timepoints. We hypothesize the intervention group compared to the control group will report lower decisional conflict about family building (primary outcome), more planning behaviors aligned with family-building goals (e.g., fertility testing, financial planning), and improved quality of life (secondary outcomes). Then, we will test mediators and moderators of intervention efficacy (Aim 2). We hypothesize age, partnership status, fertility preservation history, and engagement with the decision aid will moderate the relationship between the intervention and decisional conflict, and increased levels of knowledge and self-efficacy and improved communication with providers will mediate the intervention effect on decisional conflict. Finally, we will evaluate future implementation potential of the Roadmap tool in clinical settings (Aim 3). Guided by the Capability-Opportunity-Motivation Behavior (COM-B) implementation model, we will conduct qualitative interviews with providers representing four specialties (N=32; 8 from each) to understand barriers and facilitators to the implementation of the Roadmap tool across clinics. Providers working in diverse settings in oncology, primary care, gynecology, and reproductive medicine, all of whom address reproductive health clinically, will be included. Themes related to barriers/facilitators within the categories of ‘capability’ (e.g., skills, knowledge), ‘opportunity’ (e.g., resources), and ‘motivation’ (e.g., emotion, beliefs) will be identified. This research will comprehensively respond to the identified needs of YA-F survivors that hope to have a child after cancer through a novel intervention that provides information and support for decision making and early planning.
LOADING MOONBASE SCORE
Questions for Stanford University
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · Stanford University60
Dissecting neocortical field potential dynamics using optical voltage imaging in genetically targeted cell-types
Mark J Schnitzer · $604K · 2021–2027
- NIH · Stanford University48
Clinical Translation of Ultrasonic Ketamine Uncaging for Non-Opioid Therapy of Chronic Pain
Raag D Airan · $1.3M · 2019–2026
- NIH · Stanford University46
Innovating next generation technologies to define mechanisms of neurodegenerative disease and devise therapeutic strategies
Aaron D. Gitler · $1.1M · 2024–2032